Cost-effectiveness of pneumococcal conjugate vaccination in Georgia

Highlights • Georgia is graduating from Gavi support at the end of 2015. • Georgia evaluated the cost-effectiveness of the introduction of PCV 10. • Introduction of PCV 10 is highly cost-effective from the Georgian government perspective.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2015-05, Vol.33, p.A219-A226
Hauptverfasser:	Komakhidze, T, Hoestlandt, C, Dolakidze, T, Shakhnazarova, M, Chlikadze, R, Kopaleishvili, N, Goginashvili, K, Kherkheulidze, M, Clark, A.D, Blau, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Child, Preschool Cost-Benefit Analysis Cost-effectiveness analysis Decision-making process Economics Evidence-based medicine Georgia Georgia (Republic) - epidemiology Health Policy Humans Immunization Immunization Programs Infant Infant, Newborn Meningitis Models, Statistical Mortality Pneumococcal conjugate vaccine Pneumococcal Infections - economics Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - economics Pneumococcal Vaccines - immunology Pneumonia Streptococcus pneumoniae Vaccination - economics Vaccination - methods Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Georgia is graduating from Gavi support at the end of 2015. • Georgia evaluated the cost-effectiveness of the introduction of PCV 10. • Introduction of PCV 10 is highly cost-effective from the Georgian government perspective.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.12.070